中国P站

Obesity; Hypertension; Physiological mechanisms; Therapeutic strategies; Inflammation; Renal dysfunction; Cardiovascular health; Weight loss; Personalized medicine; Chronic kidney disease

Introduction

The complex interplay between obesity and hypertension represents a critical public health challenge, with a growing body of literature dedicated to unraveling its intricate mechanisms and therapeutic avenues. A comprehensive review explores this relationship, detailing underlying physiological mechanisms such as the activation of the renin-angiotensin-aldosterone system, sympathetic nervous system overactivity, and inflammation. It also highlights modern therapeutic strategies, including lifestyle interventions, pharmacological treatments, and surgical options, emphasizing personalized approaches to manage this complex comorbidity [1].

A systematic narrative review further examines the multifaceted connections between obesity and hypertension. It delves into the various pathways contributing to increased blood pressure in individuals with obesity, including hormonal imbalances, renal dysfunction, and vascular changes. This understanding is crucial for developing more effective prevention and management strategies [2].

Another review provides a comprehensive look at the pathophysiology of hypertension induced by obesity, exploring mechanisms like adipose tissue dysfunction, increased sympathetic tone, and oxidative stress. It critically analyzes the impact of weight loss interventions, from diet and exercise to bariatric surgery, on blood pressure reduction and overall cardiovascular health, offering insights into treatment optimization [3].

The fundamental mechanisms linking obesity to hypertension are also discussed, covering renal sodium retention, systemic inflammation, and endothelial dysfunction. Various therapeutic avenues, including traditional antihypertensive agents and novel treatments targeting specific obesity-related pathways, are explored, highlighting challenges and opportunities in managing this pervasive comorbidity [4].

The complex interplay between obesity, hypertension, and chronic kidney disease is highlighted, showing how these conditions often coexist and exacerbate each other. Recent advancements in understanding their shared pathological mechanisms are examined, along with future directions for therapeutic interventions aimed at interrupting this vicious cycle and improving patient outcomes [5].

Central obesity is identified as a distinct risk factor for hypertension, with its unique pathophysiological contributions beyond general adiposity. Mechanisms such as increased visceral fat leading to systemic inflammation, insulin resistance, and activation of the sympathetic nervous system are discussed, providing current perspectives on targeted diagnostic and therapeutic approaches [6].

Further examination reveals diverse mechanisms driving obesity-induced hypertension, ranging from genetic predispositions to the intricate interplay of hormonal and inflammatory factors. These insights inform current and future treatment strategies, emphasizing the potential for personalized medicine approaches to address the unique drivers of hypertension in individuals with obesity [7].

The critical role of adipose tissue inflammation in the development of obesity-related hypertension is explored. It details how inflammatory mediators released from dysfunctional adipose tissue contribute to endothelial dysfunction, renal sodium retention, and sympathetic nervous system activation, offering a deeper understanding of therapeutic targets focused on mitigating this inflammatory response [8].

An up-to-date overview synthesizes current knowledge on the epidemiology, pathophysiology, and clinical implications of hypertension in individuals with obesity. It outlines innovative diagnostic approaches and therapeutic strategies, including pharmacological and lifestyle interventions, while also suggesting future research directions to optimize management and improve cardiovascular outcomes [9].

Finally, the intricate mechanisms connecting obesity to hypertension are meticulously explored, detailing physiological changes in renal function, vascular structure, and neurohormonal regulation. It discusses the significant health consequences of this comorbidity and evaluates a range of therapeutic approaches, from lifestyle modifications to advanced pharmacological treatments, offering a holistic perspective on its management [10].

Description

The profound link between obesity and hypertension is a central focus of contemporary medical research, with multiple studies exploring its physiological underpinnings and clinical implications. Many investigations converge on the activation of the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system (SNS) overactivity, and chronic inflammation as primary mechanisms [1, 4, 6]. These processes collaboratively drive an increase in blood pressure, exacerbating cardiovascular risks. Renal dysfunction, often manifesting as renal sodium retention, and vascular changes, including endothelial dysfunction, are also consistently identified as key contributors to hypertension in the context of obesity [2, 4, 8, 10]. The hormonal imbalances associated with excess adiposity further complicate these physiological pathways [2, 7].

Adipose tissue, particularly visceral fat, plays a critical and often distinct role in the pathophysiology of obesity-induced hypertension [3, 6, 8]. Dysfunction in this tissue leads to the release of inflammatory mediators that contribute to systemic inflammation and oxidative stress, which in turn impact vascular health and renal function [3, 6, 8]. Insulin resistance, a common feature of obesity, also interacts with these mechanisms, further promoting sympathetic nervous system activation and affecting blood pressure regulation [6]. Genetic predispositions are increasingly recognized as influencing the susceptibility to obesity-related hypertension, suggesting a complex interplay between genetic factors and environmental influences [7]. This deeper understanding of diverse mechanisms, from genetic predispositions to intricate hormonal and inflammatory factors, informs a more nuanced approach to treatment [7].

Given the complex nature of this comorbidity, therapeutic strategies are multifaceted. Lifestyle interventions, including dietary modifications and regular physical activity, are foundational, often being the first line of defense against both obesity and hypertension [1, 3, 9, 10]. For individuals requiring more intensive management, pharmacological treatments are employed, ranging from traditional antihypertensive agents to novel therapies designed to target specific obesity-related pathways [1, 4, 9, 10]. Bariatric surgery is also presented as a highly effective intervention, significantly impacting weight loss and subsequently reducing blood pressure and improving overall cardiovascular health outcomes [3].

The broader health consequences of the obesity-hypertension link extend beyond immediate cardiovascular concerns. Notably, the coexistence of obesity, hypertension, and chronic kidney disease forms a vicious cycle, where each condition exacerbates the others [5]. Recent advancements in understanding these shared pathological mechanisms are vital for developing interventions that can interrupt this cycle and improve patient outcomes [5]. The collective research emphasizes the importance of a comprehensive understanding to develop effective prevention and management strategies, advocating for personalized medicine approaches [2, 7, 9]. These approaches aim to address the unique drivers of hypertension in individual patients with obesity, moving towards more optimized and tailored care.

The field continues to evolve, with ongoing efforts to synthesize current knowledge on epidemiology, pathophysiology, and clinical implications. Future research directions are consistently highlighted across the literature, focusing on innovative diagnostic approaches and exploring new therapeutic frontiers. The goal remains to refine management strategies and ultimately improve the long-term cardiovascular health of individuals grappling with this prevalent comorbidity [9].

Conclusion

The provided research uniformly highlights the intricate and multifaceted relationship between obesity and hypertension, emphasizing its significant impact on cardiovascular health. Various physiological mechanisms are consistently identified as underlying this comorbidity, including activation of the renin-angiotensin-aldosterone system, sympathetic nervous system overactivity, systemic inflammation, and renal dysfunction. Adipose tissue dysfunction, often linked to increased visceral fat and oxidative stress, is also frequently discussed as a key contributor, along with hormonal imbalances and vascular changes. Genetic predispositions are acknowledged as factors influencing the development of obesity-induced hypertension. Furthermore, the literature details a range of therapeutic strategies crucial for managing this complex interaction. Lifestyle interventions, such as diet and exercise, are consistently recommended alongside pharmacological treatments and surgical options like bariatric surgery for effective weight loss and blood pressure reduction. The importance of a comprehensive understanding of these underlying links is stressed for developing effective prevention and management approaches. There is a clear call for personalized medicine approaches, acknowledging genetic predispositions and targeting specific obesity-related pathways. The papers also examine the interplay between obesity, hypertension, and chronic kidney disease, underscoring shared pathological mechanisms and future directions for intervention. Overall, the research synthesizes current knowledge on epidemiology, pathophysiology, and clinical implications, offering insights into treatment optimization and future research to improve cardiovascular outcomes.

Reference

1. Alissa JW, Emily DZ, Katherine JB (2023) .Curr Hypertens Rep 25:75-87.

   , ,

2. Maria SAJP, Luís FC, Maria JG (2022) .Int J Environ Res Public Health 19:8460.

   , ,

3. Yanan Z, Yating Z, Jie D (2023) .J Hypertens 41:1205-1215.

   , ,

4. Daniel PLK, David MR, Jonathan MS (2020) .Curr Opin Nephrol Hypertens 29:161-167.

   , ,

5. Sankar DN, George LB, Peter JB (2021) .Lancet Diabetes Endocrinol 9:699-710.

   , ,

6. Naoiki F, Hironori Y, Kazuhito K (2020) .Hypertens Res 43:1010-1020.

   , ,

7. Jennifer LS, Amy LM, Jonathan MS (2021) .Curr Hypertens Rep 23:20.

   , ,

8. Yiting S, Yanling Z, Fang L (2022) .Curr Opin Nephrol Hypertens 31:121-126.

   , ,

9. Samuel M, Gian PF, Francesco SDG (2023) .Nutr Metab Cardiovasc Dis 33:1097-1107.

   , ,

10. Jing Z, Yi Z, Jian-Bin P (2022) .Eur J Pharmacol 928:175069.

    , ,